Abstract
Despite being considered "good-risk" acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG-GO) as front-line therapy of patients with CBF AML. Forty-five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG-GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML.
© 2014 Wiley Periodicals, Inc.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aminoglycosides / administration & dosage
-
Aminoglycosides / adverse effects
-
Antibodies, Monoclonal, Humanized / administration & dosage
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Core Binding Factors*
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Disease-Free Survival
-
Female
-
Gemtuzumab
-
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
-
Granulocyte-Macrophage Colony-Stimulating Factor / adverse effects
-
Humans
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / genetics
-
Leukemia, Myeloid, Acute / mortality
-
Male
-
Middle Aged
-
Survival Rate
-
Vidarabine / administration & dosage
-
Vidarabine / adverse effects
-
Vidarabine / analogs & derivatives
Substances
-
Aminoglycosides
-
Antibodies, Monoclonal, Humanized
-
Core Binding Factors
-
Cytarabine
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
Gemtuzumab
-
Vidarabine
-
fludarabine